1Drucker D, Nouck M. The incretin system: glucagon - like peptide - 1 receptor agonistes and dipeptidyl peptidase-4 inhibitors in type 2 diabetes[J]. Lancet ,2006, 368 : 1696 - 1699.
2Mudaliar S, Henry RR. Incretin therapies:effects beyond glycemic control [J]. Am Med,2009, 122 ( suppl ):S25 - S36.
3Russell- Jones D. Molecular, pharmacological and clinical aspects of liraglutide, a once - daily human GLP - 1 analogue [J]. Mol Cell Endocrinol,2009,297(2) : 137 - 140.
4Joshua J. Differdntial chemistry (structure), mechanism of action, and pharmacology of GLP - 1 receptor agonists and DPP - 4 inhibitors [ J ]. Am Pharm Assoe, 2009,49 (suppl 1 ) : S16 - S29.
5Vilsboll T, Brock B, Perrild H, et al. Liraglutide, a once - daily human GLP - 1 analogue, improves pancreatic B - cell function and arginine - stimulated insulin secretion during hyperglycaemia in patients with Type 2 diabetes mellitus [J]. Diabet Med,2008,25(2) : 152- 156.
6Garber A, Henry R, Ratner R, et al. Liraglutide versus glimepiride montherapy for type 2 diabetes ( LEAD - 3 Mono) : a randomised, 52 -week, phase 3, double - blind, parallel - treatment trial [ J ]. Lancet, 2009,373 :473 -481.
7Marre M, Shaw J, Brandle M, et al. Liraglutide, a once -daily human GLP - 1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes ( LEAD - 1 SU) [J]. Diabet Med,2009,26(3) : 268 -278.
8Nauck M, Frid A, Hermansen K, et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes) - 2 study [ J]. Diabetes Care,2009,32( 1 ) : 84 - 90,.
9Zinman B, Gefich J, Buse JB, et al. Efficacy and safety of the human glucagon - like peptide - 1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diaetes ( LEAD - 4 Met + TZD) [ J ]. Diabetes Care, 2009,32 (7) : 1224 - 1230.
10Russell -Jones D, Vaag A, Schitz O, et al. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD -5 met + SU) : a randomised controlled trial [J]. Diabetologia,2009,52(10) : 2046 -2055.
2Gracia Amalz M. obesity as disease and as social problem. GasMed Mex 2010 ;146:389 - 396.
3UK Prospective Diabetes Study ( UKPDS ) Group. Intensive blood glucose control with sulphonylures or insulin compare with con- ventional treatment and risk of complicantions in patients with type2 diabetes(UKPDS33). Lancet 1998 ;352:837 - 853.
4Gautier JF, choukemsp, Girand. Physiology of incretins ( GIP and GLP - 1 ) and abnormalities in type 2 diabetes Diabetes Metab 2008 ;34:65 - 72.
5Matthews D, Vilsboll T Courreges J, et al. Liraglutide improve p - cell function as assessed by HOMA - B and proinsulin :insulin rati- o :meta - analysis of 6 clinical trials. Diabetes,2010,59:401.
6Bode B. Liraglutide : a review of the first once - daily GLP - 1 reseptor,Am J Manag Care 2011 ;17(2Suppl) :$59 - $70.
